This is a summary of the European public assessment report (EPAR) for Hemangiol. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Hemangiol. For practical information about using Hemangiol, patients should read the package leaflet or contact their doctor or pharmacist.
Therapeutic Indication
### Therapeutic indication Hemangiol is indicated in the treatment of proliferating infantile haemangioma requiring systemic therapy: - Life- or function-threatening haemangioma, - Ulcerated haemangioma with pain and/or lack of response to simple wound care measures, - Haemangioma with a risk of permanent scars or disfigurement. It is to be initiated in infants aged 5 weeks to 5 months.
Therapeutic Area (MeSH)
ATC Code
C07AA05
ATC Item
propranolol
Pharmacotherapeutic Group
Beta blocking agents
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| propranolol hydrochloride | N/A | 普萘洛尔 |
EMA Name
Hemangiol
Medicine Name
Hemangiol
Aliases
N/A
